Wednesday, July 5th
  • About Us
  • Copyright
  • Disclaimer
  • Privacy Policy
  • Terms&Conditions
  • Contact Us
    • Advertisement
  • Site Map
Biosimilar News
  • Twitter
  • RSS
  • News/Headlines
  • Events
    • Upcoming Events
    • Past Events
  • Guidelines
  • Policies
  • Research/Analysis
USEFUL TIP: In order not to miss any updates, follow us on Twitter or sign up for our Newsletter..

Follow Us

  • Subscribe by RSS Subscribe by RSS
  • Contact us via E-Mail
  • Follow us on Twitter
  • Follow us on LinkedIn
 

Sign up for our newsletter

All-time Popular Posts

  • A biobetter trastuzumab is on the way A biobetter trastuzumab is on the way
  • EGA president calls on Member States to boost market access for biosimilars in the EU EGA president calls on Member States to boost market access for biosimilars in the EU
  • 3rd Forum on Biosimilars 3rd Forum on Biosimilars
  • Pfizer starts biosimilar rituximab Phase I/II trial Pfizer starts biosimilar rituximab Phase I/II trial
  • Indian Biosimilars Market Indian Biosimilars Market
  • World’s first biosimilar antibody* is approved in Korea World’s first biosimilar antibody* is approved in Korea
  • A biosimilar manufacturer: Celltrion A biosimilar manufacturer: Celltrion
  • 2 patents down, 1 to expire: Herceptin biosimilar coming to EU 2 patents down, 1 to expire: Herceptin biosimilar coming to EU

Archives

Twitter Updates

Archive for May, 2016

May 28, 2016 2:14 PM

World Biosimilar Congress Europe 2016

May 26, 2016 9:31 AM

Sorrento announced positive data from a combined Phase 2 & 3 clinical study of STI-004, an anti-IgE biosimilar antibody

May 25, 2016 11:52 AM

Synthon advances clinical evaluation of Anti-HER2 ADC in HER2-positive MBC patients

May 25, 2016 6:59 AM

Sandoz’ rituximab biosimilar coming to the EU

May 24, 2016 11:14 AM

Samsung Bioepis’ Biologics License Application for infliximab biosimilar accepted by FDA

© Copyright 2017 — Biosimilar News. All Rights Reserved Powered by Wordpress